-
Mashup Score: 7Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS - 1 month(s) ago
Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Navigating Emerging Therapies in Myelofibrosis Treatment - 1 month(s) ago
In an interview, Raajit K. Rampal, MD, PhD, delved into the dynamic landscape of myelofibrosis therapy, highlighting treatment options beyond JAK inhibition.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 91
Current Hematologic Malignancy Reports – Summarize best practices for management of patients with early myelofibrosis (MF). Myelofibrosis is a progressive myeloproliferative neoplasm (MPN) that…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms - John T. Milliken Department of Medicine - 2 month(s) ago
Study in Blood dissecting the role of NFκB signaling effectors in MPN disease biology Stephen T. Oh, MD, PhD, Co-Chief and Associate Professor of Medicine, Division of Hematology, Department of Medicine, Washington University School of Medicine in St. Louis, and has been published in Blood. The WashU group of researchers previously identified hyperactivation of NFκB […]
Source: internalmedicine.wustl.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 88Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee - 2 month(s) ago
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoieti
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 87Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee - 2 month(s) ago
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoieti
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis - 2 month(s) ago
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor–naive …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy? - 2 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
The unique ability of imetelstat to significantly reduce transfusion dependence and potential to modify disease in patients with lower-risk MDS who cannot receive standard ESAs may lead to improved QOL in this setting. @Sunil_G_Iyer @columbiacancer #mpnsm https://t.co/55e6j64o7T https://t.co/fMqMOmC3GE